OpGen (LTS:0A8L) Common Stock : $0.10 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is OpGen Common Stock?

OpGen's quarterly common stock increased from Mar. 2023 ($0.06 Mil) to Jun. 2023 ($0.07 Mil) and increased from Jun. 2023 ($0.07 Mil) to Sep. 2023 ($0.10 Mil).

OpGen's annual common stock declined from Dec. 2020 ($0.25 Mil) to Dec. 2021 ($0.02 Mil) but then increased from Dec. 2021 ($0.02 Mil) to Dec. 2022 ($0.03 Mil).

OpGen Common Stock Historical Data

The historical data trend for OpGen's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen Common Stock Chart

OpGen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Common Stock

Get a 7-Day Free Trial

0.06

0.25

0.02

0.03

OpGen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Common Stock	Get a 7-Day Free Trial															0.48	0.03	0.06	0.07	0.10

OpGen Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

OpGen (LTS:0A8L) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (LTS:0A8L) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

OPGN:USA 650:Germany

Address

9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850

Website

https://www.opgen.com

OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.

OpGen (LTS:0A8L) Headlines

No Headlines